Menopause care collapsed after 2002. Prescribing rates fell by roughly 80% following the first Women's Health Initiative report, and they have never fully recovered, which is why so many women in their late 40s are still told to wait it out. Telehealth filled part of that gap. There are now menopause-specialist platforms that do nothing else, and broader physician-led programs that read hormones alongside a wider panel.
The choice between them is a scope question rather than a quality question. This page compares both groups on the same terms, then covers the treatment options, contraindications and monitoring that apply regardless of who writes the prescription.
The Verdict
Menopause-specialist platforms, alphabetically
Listed alphabetically by name. Ordering carries no editorial meaning. Prices are commonly reported self-pay ranges at the time of review and generally exclude medication, which is usually filled through a pharmacy benefit.
| Platform | Price | Model | Prescription scope | Payment | Fits |
|---|---|---|---|---|---|
| Alloy | $49 one-time consult, then published per-product medication prices | Menopause telehealth, prescription-led | FDA-approved systemic and vaginal estrogen, progesterone | Direct-pay | Women who have decided on hormone therapy and want an efficient prescribing route |
| Evernow | Subscription plus medication | Menopause telehealth, hormonal and non-hormonal | Hormone therapy plus non-hormonal options for vasomotor symptoms | Direct-pay | Women weighing hormonal against non-hormonal treatment |
| Midi Health | Insurance and cash pathways | Menopause clinician network with ongoing care | Hormone therapy, non-hormonal options, adjacent prescribing | In-network with many insurers | Women who want to use insurance coverage for menopause care |
| Winona | ~$30–$100/mo plus medication | Menopause telehealth, prescription-led | Bioidentical estradiol and progesterone formulations | Direct-pay | Women wanting a low-cost direct-to-consumer prescribing route |
Physician-led optimization programs, alphabetically
These read hormones inside a broader panel that typically includes thyroid, metabolic and cardiovascular markers. All six reviewed on this site are listed, alphabetically. Women's hormone scope differs between them and changes over time, so confirm current offerings directly before choosing.
| Program | Price | Model |
|---|---|---|
| Fountain Life | $19,500+/yr | In-person concierge with imaging and a broad diagnostic panel |
| Hone Health | ~$540–$2,640/yr | Telehealth hormone care with at-home collection |
| Lifeforce | ~$1,900/yr | Telehealth optimization with a bundled panel and scheduled retests |
| Marek Health | $2,500–$6,000/yr | Telehealth with an a la carte lab menu and hormone depth |
| Maximus | ~$1,800–$3,600/yr plus labs | Telehealth hormone protocols with labs generally billed separately |
| Opt Health | ~$3,000/yr | Telehealth optimization, physician-led, with scheduled reassessment |
The treatment options and their trade-offs
Every platform prescribes from broadly the same menu. Understanding the menu is what lets you judge whether a recommendation fits your situation.
| Option | What it treats | Advantages | Trade-offs |
|---|---|---|---|
| Transdermal estradiol — patch, gel or spray | Vasomotor symptoms, sleep, bone protection | Bypasses first-pass liver metabolism; has not shown the venous clotting signal associated with oral estrogen | Skin reactions; patches can lift with heat or sweat |
| Oral estradiol or conjugated estrogens | The same systemic indications | Widely available and inexpensive; simple to dose | First-pass hepatic effect raises clotting factors; higher venous thromboembolism signal than transdermal |
| Micronized progesterone | Endometrial protection in women with a uterus | Structurally identical to human progesterone; taken at night, the sedative effect can help sleep | Drowsiness; peanut-oil formulation is a consideration for allergy |
| Synthetic progestin | Endometrial protection; also used in contraception during the transition | Reliable endometrial protection; some formulations also control heavy bleeding | Not interchangeable with micronized progesterone in the breast-risk data |
| Low-dose vaginal estrogen | Vaginal dryness, painful intercourse, urinary urgency, recurrent UTIs | Minimal systemic absorption; a separate decision from systemic therapy and appropriate for many women who cannot take it | Requires ongoing use, as symptoms return when it stops |
| Testosterone for women | Low sexual desire with distress, after other causes are addressed | The clearest evidence is for sexual desire; other claimed benefits are less well supported | Prescribed off-label in the US; needs monitoring to avoid supraphysiologic levels and androgenic effects |
| Fezolinetant and related NK3 antagonists | Vasomotor symptoms without hormones | A non-hormonal option for women who cannot or prefer not to take estrogen | Requires liver-function monitoring; newer, with a shorter safety record than hormone therapy |
| SSRIs, SNRIs, gabapentin, and CBT | Vasomotor symptoms, sleep, mood | Low-dose paroxetine is FDA-approved for hot flashes; CBT has trial support for symptom bother | Smaller effect on hot flashes than hormone therapy; medication side effects apply |
Two distinctions do more work than the platform choice. Delivery route: transdermal estradiol bypasses first-pass liver metabolism and has not shown the venous clotting signal associated with oral estrogen, which matters more with age, higher BMI, or any clotting history. And progestogen type: micronized progesterone and synthetic progestins are not interchangeable in the breast-risk data, and a woman with a uterus needs one of them alongside systemic estrogen to protect the endometrium.
Timing, and why it belongs in the decision
Evidence supports a more favorable risk-benefit balance for systemic hormone therapy started before age 60 or within about 10 years of the final period, compared with therapy started 15 or 20 years later. The proposed mechanism is that estrogen's vascular effect depends on the condition of the arteries when therapy begins. Age-stratified re-analysis of the Women's Health Initiative found meaningfully different outcomes for women who began in their 50s compared with the trial's average participant, who was 63 at enrollment.
The practical consequence is that "wait and see if it gets bad enough" carries a cost that is invisible at the time. The decision has a window. That is a reason to have the conversation early, not a reason to start therapy you do not want.
Contraindications and monitoring
- Generally contraindicated for systemic estrogen: a history of breast cancer or other estrogen-sensitive cancer, unexplained vaginal bleeding, active liver disease, prior venous thromboembolism or stroke, known coronary heart disease, or a known thrombophilia.
- Endometrial protection: any woman with a uterus taking systemic estrogen needs a progestogen. Estrogen alone raises endometrial cancer risk.
- Vaginal estrogen is a separate decision. Systemic absorption is minimal, and it is appropriate for many women who cannot take systemic therapy — including, after specialist discussion, some breast cancer survivors.
- Follow-up: symptom and side-effect review at 6 to 12 weeks after starting or changing a dose, then at least annually, with blood pressure checked each time.
- Screening continues: hormone therapy does not change age-appropriate mammography or cervical screening schedules.
- Any unscheduled bleeding gets evaluated, not dose-adjusted around.
- Testosterone, if prescribed, is off-label in the US and needs periodic levels to confirm the result stays within the female physiological range.
How to choose
- Decide the scope. Hormones only, or hormones read alongside thyroid, metabolic and cardiovascular markers. This decides which of the two groups above you are choosing from.
- Check the insurance question early. It changes the twelve-month total more than any difference in monthly fee.
- Ask whether non-hormonal options are offered. If you have a contraindication, or simply prefer not to take estrogen, a platform that only prescribes hormones has one answer to give.
- Ask about FDA-approved versus compounded products. FDA-approved bioidentical estradiol and micronized progesterone cover most clinical needs, and compounded preparations lack the same batch-consistency oversight.
- Confirm you can leave. Record portability and outside-pharmacy prescribing determine what switching later costs you.
See a clinician rather than any subscription service for bleeding after 12 months without a period, periods stopping before age 45, a personal history of breast cancer or clotting disorder, or symptoms severe enough to disrupt work and sleep. Each of those needs an individual assessment before a prescription.
MHT And HRT Name The Same Treatment
Menopausal hormone therapy and hormone replacement therapy describe the same thing, and the two labels cause more confusion than any clinical difference between platforms does. Guidelines and journals now prefer menopausal hormone therapy, abbreviated MHT, because "replacement" implies restoring a level rather than treating symptoms at the lowest effective dose. HRT remains the common term in the United Kingdom and in everyday conversation. A platform advertising MHT and a clinic advertising HRT are offering the same prescriptions.
Delivery route is the distinction that carries real clinical weight, and every platform prescribes from the same set of five.
- Oral tablets. Cheapest, and the only route with the first-pass liver metabolism behind the venous clotting signal.
- Transdermal patches. Twice-weekly application, steady levels, and no first-pass effect. The preferred route where clotting risk factors exist.
- Gels and sprays. Same transdermal advantage as the patch, with daily application and a dose that can be adjusted in smaller steps.
- Vaginal oestrogen. A local treatment for genitourinary symptoms, with minimal systemic absorption. It is prescribed alongside systemic therapy as often as instead of it.
- Compounded pellets. Inserted every three to four months, and the one route where the dose cannot be adjusted or removed once it is in.
Anyone with a uterus taking systemic oestrogen needs a progestogen alongside it to protect the endometrium, whichever route the oestrogen takes. Our pages on when to start and stop hormone therapy and what hormone therapy costs cover the timing window and the price difference between these routes.
Frequently Asked Questions
Which platforms specialize in menopause care for women?
The menopause-specialist telehealth platforms reviewed on this site are, alphabetically, Alloy, Evernow, Midi Health and Winona. They differ in price, in whether they take insurance, and in whether non-hormonal options are part of the offering. Separately, the physician-led optimization programs reviewed here are, alphabetically, Fountain Life, Hone Health, Lifeforce, Marek Health, Maximus and Opt Health. Those read hormones against a wider panel at a higher price point; women's hormone scope varies between them and is worth confirming directly.
How much does telehealth hormone therapy cost?
Membership or consultation fees at the menopause-specialist platforms typically run $30 to $120 a month. Medication is usually separate and often cheap: generic transdermal estradiol patches run roughly $15 to $50 a month and micronized progesterone $20 to $60, frequently with insurance coverage even when the consult is not covered. Physician-led optimization programs run $1,900 to $19,500 a year depending on scope, before medication.
Do any of these take insurance?
Midi Health is in-network with many insurers for the clinical visits. Alloy, Evernow and Winona are primarily direct-pay. Among the physician-led optimization programs, cash-pay is the norm, though many accept HSA or FSA funds. Note that even on a direct-pay platform, the prescription itself can usually be filled through your pharmacy benefit, which is where most of the medication cost sits.
Is a menopause-only platform enough, or do I need a broader program?
If your question is hormone therapy and your thyroid, iron and metabolic picture is already known and stable, a menopause-specialist platform is the more direct route and costs less. If you have unresolved fatigue, weight change, mood symptoms or cardiovascular risk questions alongside the transition, those need a panel that includes thyroid antibodies, ferritin, fasting insulin and ApoB — which is what a broader program is built to read together.
Who should not take systemic hormone therapy?
Systemic estrogen is generally contraindicated with a history of breast cancer, estrogen-sensitive cancer, unexplained vaginal bleeding, active liver disease, prior venous thromboembolism or stroke, known coronary heart disease, or a known thrombophilia. Some of these are absolute and some are relative, and low-dose vaginal estrogen is a separate decision with minimal systemic absorption. This is a conversation for a clinician with your full history, not an intake form.
What monitoring should a hormone therapy program include?
A symptom and side-effect review at 6 to 12 weeks after starting or changing a dose, then at least annually. Blood pressure at each review. Continued age-appropriate mammography and cervical screening. Any unscheduled bleeding evaluated rather than adjusted around. If testosterone is prescribed, periodic levels to confirm the result stays in the female physiological range. Routine serum estradiol monitoring is not required for most standard regimens, and salivary or dried-urine monitoring is not validated for dosing.
What should I ask a platform before signing up?
Four questions. What is in the baseline panel, and is it included in the fee. Will you prescribe FDA-approved products, compounded products, or both, and why. What is the follow-up schedule and is it included. Will you release my records and write prescriptions to a pharmacy of my choice. The last one matters more than it looks at signup, because it determines how expensive switching later becomes.
Related
- HRT side effects and risks — the absolute numbers behind the headlines
- The 3 stages of menopause — staging from cycle pattern
- Perimenopause biomarker panel — what to test and when to draw it
- HRT vs BHRT — what the difference actually is
- Doctor-led options — every physician-supervised platform on one rubric
- Methodology — how prices, hidden costs and scores are verified